Semaglutide is the most extensively researched GLP-1 receptor agonist, with data spanning metabolic, cardiovascular, and emerging neurological research. It has rapidly become one of the most studied pharmaceutical compounds in modern medicine.
Structural Design and Half-Life Extension
Semaglutide is structurally modified from native GLP-1 through amino acid substitutions at positions 8 and 34, a C-18 fatty diacid chain conjugated via a linker, which enables non-covalent albumin binding and results in a half-life of approximately one week — enabling once-weekly dosing in injectable formulations.
SUSTAIN Research Program (Diabetes)
The SUSTAIN clinical trial program evaluated injectable semaglutide in type 2 diabetes across multiple comparator arms. Results demonstrated superior HbA1c reductions compared to placebo, sitagliptin, exenatide ER, insulin glargine, and dulaglutide. SUSTAIN-6 demonstrated a 26% reduction in major adverse cardiovascular events (MACE) in high-cardiovascular-risk patients.
STEP Research Program (Obesity)
The STEP trials evaluated semaglutide 2.4 mg weekly for chronic weight management in people with obesity or overweight. STEP 1 demonstrated a mean weight reduction of approximately 15% from baseline over 68 weeks — a result that dramatically exceeded previous pharmacological weight loss interventions and generated substantial research interest.
SELECT Trial (Cardiovascular)
The SELECT trial examined semaglutide in people with established cardiovascular disease and obesity but without diabetes. Results demonstrated a 20% reduction in MACE, establishing cardiovascular benefit independent of glucose-lowering effects.
Emerging Neurological Research
Preclinical studies have identified GLP-1 receptors in multiple brain regions, and emerging human observational data suggests potential neuroprotective properties. Trials examining semaglutide in Parkinson's disease and Alzheimer's disease are currently underway.
Research Disclaimer: This article is for educational purposes only and does not constitute medical advice.